News

The facility has been approved by the Swiss Agency for Therapeutic Products ("Swissmedic"), the Swiss equivalent to the US FDA. Stemedica has fully executed the transfer of its

This study is a collaborative effort between MediciNova and Drs. Nazem Atassi and Haruhiko Banno, Principal Investigators at Massachusetts General Hospital’s (MGH) Neurological Clinical Research Institute (NCRI) and

Preliminary studies have demonstrated that PraediCareDx can be used to find AML patients who respond to alvocidib. Tolero is currently starting a randomized Phase II biomarker study in

Bullous pemphigoid is known to be associated with increased eotaxin-1 levels in serum and blister fluids. Immune recently started a Phase IIa open label clinical trial in bullous

GSK will increase potential milestone payments to Avalon Ventures from $40m to $50m for each biotech formed. The companies have also formed the seventh out of ten biotechs

The company completed negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, UK. Almac will occupy the formulation development and analytical testing plants

Rizaport, 5 mg and 10 mg, is an oral thin film formulation of rizatriptan benzoate. It is being developed by RedHill Biopharma and IntelGenx. It is the first

If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously. Amgen executive vice president of research and development Sean Harper said: "We’re pleased that

Xtampza ER is an extended-release, oral formulation of oxycodone, in development to manage pain severe enough for daily, long-term opioid treatment and for which alternative treatment options are